Conolidine’s analgesic effects stem from its conversation with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors in the central anxious process, conolidine modulates alternate molecular targets. A Science Developments analyze found that conolidine interacts with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availability. https://pablov319olf1.wikibyby.com/user